Radiation Oncology/Therapy: Page 234

Informatics tracking tool improves management of lung and liver cancer patients
By Cynthia E. Keen
Wednesday, November 30 | 11:40 a.m.-11:50 a.m. | SSK09-08 | Room S405ABThis presentation describes a tracking tool that red flags the failure of physicians to follow up on radiology reports that identify suspicious lung and/or liver lesions in U.S. military veterans receiving treatment in the Veterans Affairs Connecticut Healthcare System.
November 10, 2011
Int'l Isotopes gets FDA warning letter for cGMP deficiencies
By Wayne Forrest
Radioisotope manufacturer International Isotopes has received a warning letter from the U.S. Food and Drug Administration that cites several "significant violations" of current good manufacturing practice (cGMP) regulations regarding the company's sodium iodide I-131 product, which is used to treat thyroid conditions.
November 9, 2011
iCAD adds Xoft customers
By AuntMinnie.com staff writers
Computer-aided detection (CAD) firm iCAD's Xoft Axxent eBx electronic brachytherapy system for intraoperative radiation therapy has recently been installed at several hospitals.
November 8, 2011
TomoTherapy deal a mixed bag in Accuray's Q1
By AuntMinnie.com staff writers
Driven by its June acquisition of TomoTherapy, radiation therapy firm Accuray reported a sizable gain in revenues in its first quarter of fiscal year 2012, although the company's net loss also jumped.
November 8, 2011
Int'l Isotopes teams with Idaho State for copper-67
By AuntMinnie.com staff writers
Radioisotope manufacturer International Isotopes has inked an agreement in principle with Idaho State University to jointly develop processes to produce copper-67, an isotope with potential for treating non-Hodgkin's lymphoma and bladder, colorectal, and ovarian cancers.
November 7, 2011
MRI protocol developed for attenuation correction in PET/MRI for head and neck cancer
By Wayne Forrest
Wednesday, November 30 | 10:50 a.m.-11:00 a.m. | SSK13-03 | Room S505ABGerman researchers are developing a potential MRI protocol for use in a PET/MRI system to handle whole-body attenuation correction and diagnostic sequences for staging head and neck cancer patients.
November 7, 2011
FDG-PET/CT study helps detect brain changes from chemotherapy
By Wayne Forrest
Tuesday, November 29 | 3:50 p.m.-4:00 p.m. | SSJ19-06 | Room S505ABFDG-PET/CT may be a beneficial diagnostic tool to document cognitive decline, or "chemo brain," in breast cancer patients receiving chemotherapy, according to a study from West Virginia University Hospitals.
November 7, 2011
FDG-PET metabolic parameters help differentiate severity of brain tumors
By Wayne Forrest
Tuesday, November 29 | 3:20 p.m.-3:30 p.m. | SSJ19-03 | Room S505ABIn this presentation, researchers will discuss how standardized uptake values and glucose metabolic rates can help differentiate between tumors and benign lesions when evaluating patients with central nervous system lesions with FDG-PET.
November 7, 2011
Fused PET/MRI tops MR spectroscopy in brain tumor recurrence
By Wayne Forrest
Tuesday, November 29 | 3:00 p.m.-3:10 p.m. | SSJ19-01 | Room S505ABA study from the University of California, San Diego has found fused FDG-PET/MRI to be more sensitive, specific, and accurate than MR spectroscopy in detecting the recurrence of primary and metastatic brain tumors in patients with a history of grade III or IV brain tumors.
November 7, 2011
Novel tracer shows early promise for brain tumor imaging
By Wayne Forrest
Tuesday, November 29 | 11:40 a.m.-11:50 a.m. | SSG08-08 | Room S504CDIn this scientific paper presentation, researchers from Washington University School of Medicine will present their work on a novel synthesized tracer that so far has shown promising tumor imaging properties in the potential to complement MRI for evaluating patients with primary and metastatic brain tumors.
November 7, 2011
Ga-68 DOTA-NOC tops F-18 DOPA-PET/CT for neuroendocrine tumors
By Wayne Forrest
Tuesday, November 29 | 10:50 a.m.-11:00 a.m. | SSG12-03 | Room S505ABIn a comparison with F-18 DOPA-PET/CT, gallium-68 (Ga-68) DOTA-NOC achieved "superior sensitivity" with neuroendocrine tumors, prompting researchers to conclude that Ga-68 DOTA-NOC could help direct more effective patient treatment.
November 7, 2011
Medspira to show upgraded Breath Hold
By AuntMinnie.com staff writers
Respiratory motion monitoring technology developer Medspira plans to show an advanced version of its Breath Hold standalone system for multiple imaging modalities at this month's RSNA meeting in Chicago.
November 6, 2011
Previous Page
Page 234 of 468
Next Page